American Century Companies boosts stake in Biohaven, ETF Daily News says
American Century Companies has boosted its stake in Biohaven (BHVN) by 9.5% during Q4, ETF Daily News reports, citing a recent SEC filing. The firm owned 558,761 shares of Biohaven after purchasing an additional 48,286 shares during the period, the report notes.
Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks.
Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today's best-performing stocks on TipRanks >>
Read More on BHVN:
Disclaimer & DisclosureReport an Issue
Biohaven falls -10.9%
Immunovant data positive for Biohaven, says Deutsche Bank
Positive Outlook for Biohaven Ltd. Amid Promising Developments and FDA Priority Review
Biotech Alert: Searches spiking for these stocks today
Optimistic Buy Rating for Biohaven Ltd. Amid Promising Drug Developments and Strategic Pipeline Advancements
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development
NEW HAVEN, Conn., June 10, 2025 (GLOBE NEWSWIRE) -- Bexorg, Inc., a pioneering techbio company working to decode the human brain and advance new therapies for central nervous system (CNS) disorders, today announced a multi-program research collaboration with Biohaven Ltd. (NYSE: BHVN) to identify, de-risk, and advance next-generation therapies for CNS disorders. As part of the collaboration, Bexorg's novel whole-brain discovery platform will be used to demonstrate target engagement in relevant cell types and tissues and generate novel biomarkers, pharmacokinetic and pharmacodynamic relationships, and other mechanistic data to support two preclinical development programs at Biohaven. Bexorg's whole-brain discovery platform is the only technology capable of perfusing isolated, cadaver human and pig brains with custom-made artificial blood, thereby restoring metabolic and molecular activity for prolonged periods. Bexorg's founders developed the whole-brain perfusion technology at Yale University. Using it, the company can extract high-resolution transcriptomic, proteomic, and metabolic insights in disease-relevant states. With this information, Bexorg is building the largest and most physiologically relevant datasets in human neurodegeneration to enable machine learning and artificial intelligence (AI)-centered CNS drug discovery and development. This breakthrough aims to provide unparalleled insights into human brain molecular activity and advances in the understanding of CNS disorders. 'Our technology enables preclinical testing of almost any therapeutic in metabolically active whole human brains, whether diseased or non-diseased, providing a significant advantage over any other preclinical model in neuroscience,' said Zvonimir Vrselja, MD, PhD, CEO and Co-founder at Bexorg. 'Our ability to collect longitudinal data from our whole-brain discovery platform allows us to validate new targets and biomarkers and understand the pharmacokinetic and pharmacodynamic profiles and potential safety and effectiveness of drugs before going into the clinic. We are thrilled to team up with Biohaven to help advance two preclinical programs and potentially unlock a faster, more precise path to new CNS therapies.' 'The lack of robust translational preclinical models that adequately capture the complexity of human brain structure and function, including the architecture and dynamics of neural networks comprised of billions of neurons and glial cells and the trillions of connections that exist between them, and account for physiological gradients of drug exposure throughout the brain associated with distinct profiles of drug transport across the blood-brain barrier, has, until now, severely handicapped CNS drug discovery and development,' said Bruce D. Car, DVM, PhD, DACVP, Chief Scientific Officer at Biohaven. 'Bexorg's novel platform effectively overcomes the myriad deficiencies inherent in this translational gap, permitting unprecedented and detailed insights into the CNS pharmacology, dosimetry, and potential efficacy of drug candidates before advancing to costly and time-consuming clinical trials.' As part of the collaboration, Bexorg aims to deliver insights from systemic delivery of Biohaven's therapeutics, including analysis of pharmacokinetics, pharmacodynamics, and mechanism of action. Data generated from the platform may also potentially point to the responsiveness of patient subpopulations and identify novel biomarkers to inform clinical trials. Financial terms of the collaboration were not disclosed. About BiohavenBiohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Biohaven is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and nonclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for OCD and SCA (spinocerebellar ataxia); myostatin inhibition for neuromuscular and metabolic diseases, including SMA and obesity; antibody recruiting bispecific molecules and antibody drug conjugates for cancer. For more information, visit About BexorgBexorg is a privately held techbio company with the first-ever full-stack tech platform to support central nervous system (CNS) drug discovery and development in the human brain in a way that has not been possible before. Bexorg is building a drug discovery artificial intelligence (AI) loop based on its proprietary wet-lab platform, BrainEx, which enables restoration of molecular activity in postmortem human brains to generate high-fidelity, clinically predictive data, model drug response, and create a foundation model for CNS discovery. The company is generating large volumes of human brain data to train predictive models across diseases. Bexorg is building an AI engine, XO Digital, which learns from each experiment, creating a closed-loop system of in-silico prediction and wet-lab validation. With this fully integrated platform, Bexorg is setting a new standard for CNS translational and discovery research. In collaboration with the National Institutes of Health (NIH), Bexorg's founders have been at the forefront of bioethics in postmortem brain molecular recovery research, and the company has an independent board comprised of bioethics leaders to ensure its operations maintain the highest standards. Bexorg is strategically partnering with leading neuroscience companies to integrate its platform into clinical development programs, as well as advancing in-house neurodegeneration assets. Visit us at and follow us on LinkedIn to learn more. Biohaven's Forward-looking StatementsThis news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'next generation', 'most', 'unparalleled', 'largest', significant', 'novel', 'unprecedented', and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable US regulatory requirements; the potential commercialization of Biohaven's product candidates; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this news release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. CONTACT: Bexorg Media Contact: Adam Silverstein SCIENT PR adam@ Biohaven Contacts: Investor Contact: Jennifer Porcelli Vice President, Investor Relations +1 (201) 248-0741 Media Contact: Mike Beyer Sam Brown Inc. mikebeyer@ +1 (312) 961-2502
Yahoo
29-05-2025
- Yahoo
Biohaven Ltd. (BHVN)'s BHV-1400 Cuts Disease Antibody by 81% in IgA Nephropathy
Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and BHV-1300, at its 2025 R&D Day in New Haven. BHV-1400, a first-in-class TRAP degrader, achieved up to 81% reduction in galactose-deficient IgA1 (Gd-IgA1), the key driver of IgA nephropathy (IgAN), after a single subcutaneous dose, with effects lasting for weeks. A patient viewing their medical diagnosis on a digital healthcare ecosystem. Unlike traditional immunosuppressive treatments, BHV-1400 precisely eliminates pathogenic Gd-IgA1 while sparing healthy antibodies (IgA, IgG, IgE, IgM), preserving overall immune function and offering a superior safety profile. This selectivity sets it apart from complement and BLyS/APRIL inhibitors, which can compromise broader immunity. Encouraged by these results, Biohaven Ltd. (NYSE:BHVN) will launch a pivotal IgAN trial in 2026 using the urine protein-creatinine ratio as an accelerated approval endpoint. Simultaneously, BHV-1300, targeting IgG-mediated diseases like Graves' Disease, demonstrated rapid, deep, and sustained total IgG reductions of up to 87% in Phase 1, with flexible dosing for acute and chronic management. Both therapies were well-tolerated, with no serious adverse events. Biohaven Ltd. (NYSE:BHVN) plans pivotal trials for BHV-1300 in Graves' Disease in the second half of 2025, reinforcing its leadership in precision immunology. While we acknowledge the potential of BHVN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BHVN and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
28-05-2025
- Yahoo
In Your Neighborhood: Kathryn Hauser at MADE Leadership Series event at Yale Innovation Summit
NEW HAVEN, Conn. (WTNH) — News 8's Kathryn Hauser emceed the second MADE Leadership series on Wednesday in New Haven. The series was held at the Yale Innovation Summit and featured discussions on the state of innovation in Connecticut. The panel was moderated by the state's Chief Innovation Officer and Department Of Economic and Community Development Commissioner Dan O'Keefe. Also on the panel were CEOs of Biohaven, BioCT and QuantumCT. 'For me, innovation is not just disrupting, but it's actually solving big patient problems and healthcare problems, said Biohaven CEO Dr. Vlad Coric. The Yale Innovation Summit is a two-day event that features exhibits, discussions and dynamic experiences. 'What I love about Connecticut, is we all band together to really lure the companies,' said BioCT CEO Jodie Gillion. 'We can get together with Yale, with the state, with Connecticut innovations and all different groups and really put on a good show.' The next MADE Leadership Series event will take place in October in Fairfield County. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
